Pregabalin- and azithromycin-induced rhabdomyolysis with purpura: An unrecognized interaction: A case report

Kazuya Kato1, Yoshiaki Iwasaki2, Kazuhiko Onodera3

  • 1Department of Surgery, Pippu Clinic, 2-10, 1 cyome Nakamachi, Pippu Town Kamikawa-gun, Hokkaido 078-0343, Japan.

Abstract

Insights

This case report details an extremely rare instance of rhabdomyolysis with purpura, a serious condition, linked to the combined use of pregabalin and azithromycin.

Area of Science:

  • Pharmacology
  • Toxicology
  • Clinical Medicine

Background:

  • Rhabdomyolysis is a rare but serious adverse event associated with pregabalin and azithromycin use.
  • This report highlights an exceptionally uncommon presentation of rhabdomyolysis accompanied by purpura.

Purpose of the Study:

  • To report a unique case of rhabdomyolysis with purpura in a patient using both pregabalin and azithromycin.
  • To investigate the potential drug interaction between pregabalin and azithromycin leading to rhabdomyolysis.

Main Methods:

  • Case presentation of a 75-year-old female patient with fibromyalgia.
  • Detailed medical history including pregabalin for chronic pain and azithromycin for acute bronchitis.
  • Clinical examination and laboratory findings including elevated creatinine phosphokinase (CPK).

Main Results:

  • The patient presented with limb weakness, purpura, myalgia, edema, and gait instability.
  • Laboratory results showed a significantly elevated white blood cell count and CPK level.
  • Diagnosis of drug-induced rhabdomyolysis attributed to pregabalin and azithromycin interaction.

Conclusions:

  • The concurrent use of long-term pregabalin and initiation of azithromycin therapy preceded the rapid onset of rhabdomyolysis.
  • This case suggests a potential drug interaction between pregabalin and azithromycin.
  • The exact mechanisms underlying this interaction remain to be elucidated.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
900
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
594
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
836
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
309
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
325
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
238